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patient’s involvement and better health outcomes. Improving service development 
and access to health advice with care experience are other adjuvant interventions. 
So patient’s participation is a key better care plan.
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TurkisH Public ProcuremenT sysTem for medical devices:a Guide for 
reimbursemenT Policy?
Seyhun O., Can H., Erdol S., Erdogan Ciftci E.
Medtronic, Inc., Istanbul, Turkey
In 2008, Public Procurement Law (PPL) was amended to implement and regulate 
e-Procurement in Turkey. Non-private, public purchaser hospitals are obliged to 
enter tender results of their medical device purchases into e-procurement system 
(EPS) to be eligible for a reimbursement by the Social Security Institution (SSI) in 
Turkey. Objectives of this research are to examine the impact of the EPS that is 
currently being used for medical device purchases in Turkey since 2011; and to 
investigate how the system is being used to define ceiling prices for reimbursement, 
concurrently assessing the quality and quantity of data uploaded by hospitals. EPS 
data is downloaded on a GMDN basis from Turkish National Database for Medical 
Devices, (TITUBB) which is an e-catalogue system that was launched to provide bar-
code level product registration, search and the e-procurement results. In accordance 
with the objectives, assessment is conducted on more than ten GMDNs and results 
are utilized to see the effect of EPS on pricing, comparing the prices on officially 
published SSI positive lists. Our study shows that a lowest price detected on EPS 
could be set as the reimbursement price, as was the case for the product; aortic stent 
graft, contralateral limb, where a defined SSI positive list price was reduced after 
determination of a lower price on EPS, on account of  a mispriced tender record. 
An extrapolation while searching out the reimbursement prices is needed instead 
of SSI’s calculations based on merely a retrospective and detection of lowest price 
practice. Effectiveness of this policy depends on resolving the weaknesses of EPS 
data in terms of quality and quantity; a misdated tender or a mispriced product 
could be a ground for an erroneous price setting and tenders that are not recorded 
at all or deferred might lead to incomplete EPS data to define reimbursement prices.
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Objectives: Second-generation antipsychotic drugs, knows as Atypical 
Antipsychotics, have a better tolerability than conventional antipsychotics but it 
has reported that its usage lead to a substantial weight gain, an increase risk of 
dyslipidemia and type 2 diabetes mellitus. In this article authors assessed the risk 
of metabolic adverse events associated with Asenapine in comparison with those 
associated with Olanzapine by studying real world data. MethOds: The study was 
a retrospective analysis based on data extracted from Italian and Spanish Cegedim 
Stategic Data Longitudinal Patient Data databases. Patients were divided in two 
cohorts (Asenapine and Olanzapine) according to the inclusion criteria and data 
from these patients were analyzed starting from 2009 up to 2013. Diabetes and 
dyslipidemia registrations have been searched in order to assess the risk of develop-
ing metabolic adverse events. Results: The retrospective analysis showed a lower 
risk of developing type 2 diabetes and dyslipidemia associated with Asenapine 
treatment in comparison with Olanzapine. Scenario analyses supported the robust-
ness of the results. cOnclusiOns: Asenapine is associated with a lower risk of 
metabolic adverse events than Olanzapine, demonstrating a better safety profile 
with regard to metabolic effects.
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Objectives: The purpose of this study was to apply a systematic review of the 
literature to evaluate the diagnostic effectiveness of the Phosphorylated tau p181 
for the Alzheimer’s disease dementia. MethOds: A systematic literature review 
was used to evaluate the effectiveness of of the Phosphorylated tau p181 for the 
Alzheimer’s disease dementia. The Scottish Intercollegiate Guidelines Network 
(SIGN) tool was used by two evaluators to independently evaluate the quality of the 
ten studies. The literature review covered from October 27, 1946 to October 22, 2013, 
and eight domestic databases including KoreaMed and foreign databases includ-
ing Ovid-MEDLINE, EMBASE, and Cochrane Library were used. Results: A total of 
9studies (9 diagnostic evaluation studies) were identified to evaluate Phosphorylated 
tau. Theeffectiveness of this test was evaluated based on diagnostic accuracy. The 
diagnostic accuracy for identifying AD of ELISA was high (pooled sensitivity, 0.843 
(95% CI 0.818-0.867); pooled specificity, 0.799 (95% CI 0.768-0.828); summary receiver 
operating characteristic area under the curve 0.9082±0.0236. Primary criteria for 
inclusion were valid studies on (i) patients with mild cognitive impairment with 
confirmed or suspected AD and non-AD dementia, and (ii) assessment of tau levels 
using appropriate comparative tests. cOnclusiOns: Evaluated CSF Phosphorylated 
tau levels are of potential utility in the differential diagnosis of AD versus non-AD 
dementias and healthy controls.
of options and requirements by country. The evaluation of market access options for 
OD-HOM can ease market access and reimbursement and influence international 
launch sequences of innovative orphan drugs.
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Objectives: Despite the growing interest in observational studies, there is any 
defined regulatory process unlike clinical trials, which have a defined one. Currently, 
international observational studies have to deal with each county regulatory process 
that means to face times and costs very heterogeneous and not regulated yet by 
the EU. Here we report the experience of MediData in international observational 
study conduct. MethOds: The start-up process in 7 countries was analyzed as for 
regulatory process in terms of time and costs. Results: In Europe the faster regu-
latory process takes 12 weeks (Turkey) and the slowest one takes almost twice as 
long (Italy 24 weeks), while in the USA they spend almost 16 weeks to conclude the 
whole process. Usually times and costs have an inverse relationship, but the observa-
tional studies analyzed shows that the second cheaper country is Turkey, that comes 
after France where the process is free. Another example of this variety is the case of 
Spain and France in the same duration of the process have a difference of spending 
of 12000 € . cOnclusiOns: These duration and spending really differentiated 
have a huge impact on the observational study conduction. Especially at the inter-
national level, we might run into sponsored studies which could be conducted in 
countries with cheaper or faster regulation processes, with the real risk of a selection 
bias of the sites and, therefore, a very partial collection of data. Inevitably, the result 
will be unrepresentative epidemiological data. It’s very important to have a pan-Euro-
pean regulation that allows the observational study conduction in an homogenous 
and aligned way and also to have complete and representative epidemiological data.
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bAckgROund: Hydroxycarbamid is an antineoplastic molecule commercialized 
since 1968 in France under the name Hydrea®. In the absence of an alternative 
licensed drug for the treatment of Sickle Cell Syndrome (SCS), Hydrea® has been rou-
tinely used off-label for over 15 years in this indication. In 2007, Siklos® became the 
first licensed orphan drug indicated in the symptomatic treatment of SCS. However, 
during the pricing and reimbursement procedures, the French Transparency 
Committee decided to compare Siklos® to Hydrea® and as such Siklos® was evalu-
ated as bringing a weak additional benefit (ASMR IV) which had a major impact on 
the price given by the French Economic Committee on Health Care Products (CEPS). 
The manufacturer of Siklos® entered in litigation with the CEPS and after a long 
legal procedure, the French Council of State issued two orders by way of interlocu-
tory procedures suspending the decision of the drug price setting and determining 
the minimal threshold under which Health Authorities could not set the price of 
this drug. discussiOn: The negative assessment of the French HTA could have set 
a precedent for future evaluations of orphan or pediatric medicines issued from 
drug repurposing. These decisions are unique in the history of the Council of State’s 
jurisprudence on several aspects: it was an unprecedented case where a CEPS deci-
sion is overturned by the Council of State and the first time that a judicial decision 
provides guidance on the price level for a pharmaceutical drug in France. This case 
law has also the consequence to enlarge the criteria taken into account by the CEPS 
in new drug price setting, especially for orphan drugs. cOnclusiOn: Siklos® case 
law provided a new legal ground that is in contradiction with available regulation 
and practice and opens the way for future legal challenges to the CEPS decisions.
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Objective: Patient’s involvement in their health care is important to improve qual-
ity, efficacy and better patient care. It is a strategy to achieve improved health 
outcomes and lower costs. A main objective of the discussion is focused on “how 
to inform, encourage and educate the patient to participate in their health care 
decisions?” The purpose of the discussion also centered on the various patients 
focused interventions required to improve the health care outcomes by patient’s 
participation. bAckgROund: All patients want the information about the disease 
and complications they have, but not all want to involve in decision making. Most of 
the patients preferred to leave the final decision on doctors/clinicians. Engagement 
of patients in health care and decision making would improve the health outcomes 
and lowering the cost of therapy or treatment. discussiOn: Health care is a com-
plicated system to patients; they struggle to understand their medical conditions 
and services. All patients must have to know about basic health information and 
treatment options. This would be possible by encouraging patient’s to play an active 
role in their health care that could improve health outcomes, efficiency and quality. 
Patient’s participation and engagement are based on patient activation which refers 
to understanding, ability, health literacy and willingness of patient to manage his or 
her health and care. Patients can participate at different levels as direct care or their 
preference in treatment plan and/or in policy making for future recommendations. 
Patient focused interventions are discussed as companion to patient’s participation 
or engagement. Improvement in health literacy, patient safety, improvement in self 
care and clinical decision making are four primary interventions which promote the 
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compared with GXR, ATX, and MPH in the treatment of children and adolescents 
with ADHD with no overlap in CrIs. Among non-stimulants, although GXR had a 
higher probability of being more efficacious than ATX, their CrIs overlapped.
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Objectives: The objective of this study was to assess the comparative effective-
ness of clomethiazole against diazepam in the treatment of alcohol withdrawal 
syndrome (AWS) in the real-world. MethOds: Following a retrospective design, 
this study is based on case report notes of patients consecutively treated for AWS 
at a University Clinic in Germany (Aachen), from 2008 to 2013. The primary out-
comes were: scores of German version of the revised clinical institute withdrawal 
assessment for alcohol scale (CIWA-Ar) in the first four days of therapy; duration 
of therapy; duration of hospital stay and rates of complications. Patients in the two 
groups (diazepam and clomethiazole) were matched for demographic factors and 
severity of withdrawal using propensity scores. Results: Seventy nine patients 
(Diazepam = 42; Clomethiazole = 37) were included. Mean age of patients (M = 
69%, F = 30.4%) was 45±15 years. Duration of excessive alcohol use was 16 ± 12 
years. On admission mean systolic and diastolic blood pressure was 139±20 and 
88±13, respectively. Pulse rate was 100 ±18 per minute. CIWA-Ar scores at the end 
of each of the first four days of therapy were not statistically significantly different 
(ANOVA, p < 0.5) for the two therapies. Average duration of therapy was 3.81±2.9 
days vs. 5.8 ±3.2 days (ANOVA - F = 8.6, p = 0.004), for clomethiazole and diazepam 
groups, respectively. Duration of hospital stay was 14.92±10.1 vs. 15±13 (ANOVA – 
F, p > 0.2), respectively. There was no difference in complication rates, except for 
seizures (higher in Diazepam group, Chi-square test, p = 0.023). cOnclusiOns: 
Clomethiazole and Diazepam seem to offer comparable effectiveness in resolving 
symptoms of AWS. Otherwise the notably shorter therapy duration and lower rates 
of complications for clomethiazole hints at some advantages such as faster recovery 
and lower costs of treatment, although this would have to be confirmed in future.
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Objectives: To understand the potential predictors of remission among patients 
treated for major depressive disorder (MDD) in a naturalistic clinical setting in 
the Middle East. MethOds: Data for this post-hoc analysis were taken from a 
6-month prospective, non-interventional, observational study that involved 1,549 
MDD patients without sexual dysfunction at baseline in twelve countries world-
wide (n= 314 in the Middle East). Depression severity was measured using Clinical 
Global Impression of Severity (CGI-S) and 16-item Quick Inventory of Depressive 
Symptomatology Self-Report (QIDS-SR16). Depression-related pain was measured 
using the pain-related-items of Somatic Symptom Inventory (SSI). Remission was 
defined as a QIDS-SR16 score ≤ 5. Generalised estimating equation (GEE) regres-
sion model was used to examine baseline factors associated with remission at 
each follow-up visit. The model included age, sex, region, CGI-S score, QIDS-SR16 
total score, SSI pain total score, and treatment (duloxetine vs. a selective serotonin 
reuptake inhibitor [SSRI] ) at baseline. Other baseline factors were also included if 
they appeared to be significant at p< 0.1 in simple GEE models. The model analysed 
the patient observations up to the point where their initial medications were main-
tained. Results: Of the 240 patients analysed, 133 (55.4%) initiated duloxetine and 
107 (44.6%) initiated an SSRI at baseline. Of these, 199 patients achieved remission 
at any visit during follow-up (91.0% in the duloxetine group and 72.9% in the SSRI 
group, p< 0.001). The GEE results showed that higher QIDS-SR16 scores at baseline 
(odds ratio [OR]= 0.88, p= 0.002) and more MDD episodes in the past 24 months 
(OR= 0.77, p< 0.001) were negatively associated with remission, whereas treatment 
with duloxetine (vs. SSRIs) was positively associated with remission (OR= 2.78, 
p< 0.001). cOnclusiOns: Treatment with duloxetine (vs. SSRIs), a lower level of 
depression severity and fewer previous MDD episodes appeared to be strong predic-
tors of achieving remission in the treatment of MDD in the Middle East.
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Objectives: Obsessive compulsive disorder (OCD) is the fourth most common 
mental disorder in the UK with a prevalence of 1.5%. Both pharmacological and 
psychological interventions are used in the treatment with the treatment course 
usually chronic. This study estimates the relative efficacy of pharmacological 
and psychological treatments or combinations of both. MethOds: A systematic 
review was conducted to identify RCTs of clomipramine, SSRIs, venlafaxine, and 
psychological interventions with a behavioural, cognitive or cognitive behavioural 
component. A Bayesian random effects network meta-analyses (NMA) was used to 
obtain coherent estimates of relative efficacy of every pair of the different inter-
ventions, even when direct evidence was not available. The primary endpoint was 
mean change in Yale-Brown obsessive compulsive scale (YBOCS). We assumed that 
treatment effects for the different SSRIs were similar in the sense that they came 
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Objectives: MyCognition has already demonstrated that its adaptive video game 
programmes are able to enhance cognitive health in healthy volunteers (FENS, July 
2014). It is now using the same technology to assess and train cognitive health 
in psychiatric and neurological patient populations that have cognitive impair-
ment. MethOds: In both the psychiatric and neurological patient population it is 
planned that all with have their cognitive health assessed prior to commencement 
of the study to provide a baseline score. This will be for the 5 key cognitive domains 
(attention, psychomotor speed, episodic memory, working memory and executive 
functioning). All will then be randomised to either active or control group. The 
active group comprises adaptive video training of at least one hour per week over 
a 12-week period on top of standard care. The control group receives standard care 
alone. All the subjects will have their cognitive health assessed at 0, 4, 8 and 12 
weeks. They will also have their condition assessed via a specific scale, e. g., PANS for 
Schizophrenia, UPDRS for Parkinson’s. The results will be calculated as change from 
baseline for both groups at 4, 8 and 12 weeks. Results: In previous tests in healthy 
volunteers a significant improvement in cognitive health was seen after 4 weeks of 
training. By 8 weeks it was possible to see a dose response to the duration of training, 
with longer training showing a greater effect. cOnclusiOns: Detrimental cognitive 
health is seen in many neuropsychiatric conditions. To date, drug therapies have 
had a poor impact on cognitive disorders. This adaptive video training programme 
presents a potential therapeutic intervention that is safe and effective. The online 
assessment can be used to profile at risk subjects and the training could be used to 
prevent as well as treat cognitive decline.
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Objectives: The costs of mental health care for patients with severe and com-
plex personality disorders are high. It is likely that currently, these patients are 
not treated effectively due to limited early recognition. The aim of this study is to 
develop a set of criteria to match patients with severe and complex personality dis-
orders to effective treatment in highly specialized treatment programs. MethOds: 
The subsequent steps consisted of conducting a literature search, applying concept 
mapping, arranging an expert-meeting and validating the set of criteria. After the 
literature search, concept mapping, using cluster analysis and multidimensional 
scaling, was conducted. Goodness of fit and reliability were tested. A consensus 
meeting was arranged to determine cut-off points and operationalize the clus-
ters. In this way, the definite set of criteria for matching patients with severe and 
complex personality disorder was developed. A pilot study on the checklist was 
conducted, including 20 therapists evaluating 45 patients and subsequently a valida-
tion study at 8 mental health institutes was performed. Additionally, a methodology 
to obtain sets of criteria for other psychiatric diagnoses was developed. Results: 
After the literature search and concept mapping, 6 different categories of criteria 
were defined. The concept mapping model provided a good fit (stress value= 0.30) 
and reliability (ρ = 0.49) was reasonably high. The bridging values were on general 
low, indicating homogeneity. The pilot study indicated that clinical judgment and 
the outcome of the checklist correlated high (0.8). The validation study has been 
accomplished at 8 mental health institutes in the Netherlands. The analysis con-
cerning the validation study is now being conducted and the first results will be 
available in August 2014. cOnclusiOns: The method is systematic, structured and 
repeatable and the results of the pilot study are promising. The protocol will provide 
an instrument to develop sets of criteria for other disorders to increase matching of 
patients in mental health care to (cost) effective interventions.
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Objectives: This study compared the clinical efficacy of ADHD treatments in chil-
dren and adolescents. MethOds: A systematic literature review was conducted, 
according to National Institute for Health and Care Excellence guidelines, to identify 
randomized controlled trials (RCTs) of guanfacine (GXR), atomoxetine (ATX), lisdexa-
mfetamine (LDX), and methylphenidate (MPH) extended release (ER) and immediate 
release (IR) in children and adolescents with ADHD. A Bayesian mixed treatment 
comparison was conducted to compare baseline-to-endpoint change in ADHD-
RS-IV score, response (defined as a clinician global impressions – improvement 
[CGI-I] score ≤ 2), with meta-regression adjustments permitted by data availability 
(age and percent female). 95% credible intervals (CrIs) for treatment effects and 
the posterior probability that GXR was more efficacious than each treatment were 
estimated. Results: Of 5,619 records retrieved, 29 RCTs met the inclusion criteria. 
Five trials included GXR, 4 included LDX, 16 included ATX, 7 included MPH-ER, and 
5 included MPH-IR. Per-arm patient sample size ranged from 29 to 222. The mean 
ADHD-RS-IV score change from baseline and 95% CrI (active minus placebo) were 
-8.68 (-10.63, -6.72) for GXR, -14.98 (-17.14, -12.80) for LDX, -6.88 (-8.22, -5.49) for ATX, 
and -9.33 (-11.63, -7.04) for MPH-ER. The relative risk and 95% CrI for CGI-I response 
(drug vs placebo) were 2.13 (1.68, 2.59) for GXR, 2.93 (2.47, 3.40) for LDX, 2.30 (1.79, 
2.81) for MPH-ER, 1.97 (1.43, 2.58) for ATX, and 1.66 (1.02, 2.32) for MPH-IR. Among 
non-stimulants, GXR was more effective than ATX when comparing ADHD-RS-IV 
change (with a posterior probability of 93.91%) and CGI-I response (posterior prob-
ability 71.01%). cOnclusiOns: This review found that LDX had greater efficacy 
